Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 35Kidney Neoplasms 8Neoplasms 6Neoplasm Metastasis 6Carcinoma, Non-Small-Cell Lung 6Melanoma 5Carcinoma, Hepatocellular 5Colorectal Neoplasms 4Recurrence 3Lung Neoplasms 3Glioblastoma 3Carcinoma 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Sarcoma 2Pheochromocytoma 2Paraganglioma 2Liver Neoplasms 2Endometrial Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Adenoid Cystic 2cT2a N0NxM0 Renal Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Solitary Fibrous Tumors 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Relapsed Pediatric Solid Tumor 1Radiation Therapy 1

Interventions

vandetanib 1ruxolitinib 1pazopanib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Ifosfamide 1Everolimus 1Etoposide 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Carboplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Relapsed Pediatric Solid Tumor × Axitinib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡